Literature DB >> 11014634

In vitro activity of a new liposomal nystatin formulation against opportunistic fungal pathogens.

G Quindós1, A J Carrillo-Muñoz, M T Ruesga, R Alonso-Vargas, Y Miranda, C Tur-Tur, M Rubio, T L Wallace, P A Cossum, E Martín-Mazuelos, R Cisterna, J Pontón.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11014634     DOI： 10.1007/s100960000334

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


× No keyword cloud information.
  4 in total

1.  In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis.

Authors:  Cristina Marcos-Arias; Elena Eraso; Lucila Madariaga; Alfonso Javier Carrillo-Muñoz; Guillermo Quindós
Journal:  Mycopathologia       Date:  2011-08-14       Impact factor: 2.574

2.  In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates.

Authors:  Sevtap Arikan; Luis Ostrosky-Zeichner; Mario Lozano-Chiu; Victor Paetznick; David Gordon; Tom Wallace; John H Rex
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

3.  In Vitro Antifungal Susceptibility of Oral Candida Isolates from Patients Suffering from Caries and Chronic Periodontitis.

Authors:  Janire De-la-Torre; María Esther Ortiz-Samperio; Cristina Marcos-Arias; Xabier Marichalar-Mendia; Elena Eraso; María Ángeles Echebarria-Goicouria; José Manuel Aguirre-Urizar; Guillermo Quindós
Journal:  Mycopathologia       Date:  2017-01-25       Impact factor: 2.574

Review 4.  Fungal diseases: could nanostructured drug delivery systems be a novel paradigm for therapy?

Authors:  Aline Raquel Voltan; Guillermo Quindós; Kaila P Medina Alarcón; Ana Marisa Fusco-Almeida; Maria José Soares Mendes-Giannini; Marlus Chorilli
Journal:  Int J Nanomedicine       Date:  2016-08-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.